JP2016517421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517421A5 JP2016517421A5 JP2016502232A JP2016502232A JP2016517421A5 JP 2016517421 A5 JP2016517421 A5 JP 2016517421A5 JP 2016502232 A JP2016502232 A JP 2016502232A JP 2016502232 A JP2016502232 A JP 2016502232A JP 2016517421 A5 JP2016517421 A5 JP 2016517421A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- adamts13
- hours
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000043853 ADAMTS13 Human genes 0.000 claims description 41
- 108091005670 ADAMTS13 Proteins 0.000 claims description 41
- 238000001990 intravenous administration Methods 0.000 claims description 30
- 238000007920 subcutaneous administration Methods 0.000 claims description 22
- 230000037396 body weight Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 9
- 208000015294 blood coagulation disease Diseases 0.000 claims description 9
- 206010063837 Reperfusion injury Diseases 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 206010008118 cerebral infarction Diseases 0.000 claims description 7
- 208000035888 Immune-mediated thrombotic thrombocytopenic purpura Diseases 0.000 claims description 6
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 6
- 208000004886 acquired thrombotic thrombocytopenic purpura Diseases 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 208000032843 Hemorrhage Diseases 0.000 claims description 5
- 208000034158 bleeding Diseases 0.000 claims description 5
- 230000000740 bleeding effect Effects 0.000 claims description 5
- 230000003203 everyday effect Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 101000798281 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 13 Proteins 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 102000057210 human ADAMTS13 Human genes 0.000 claims description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 47
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794659P | 2013-03-15 | 2013-03-15 | |
| US61/794,659 | 2013-03-15 | ||
| PCT/US2014/026747 WO2014151968A1 (en) | 2013-03-15 | 2014-03-13 | Subcutaneous administration of adamts13 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019025097A Division JP6998333B2 (ja) | 2013-03-15 | 2019-02-15 | Ａｄａｍｔｓ１３の皮下投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016517421A JP2016517421A (ja) | 2016-06-16 |
| JP2016517421A5 true JP2016517421A5 (enExample) | 2017-04-13 |
| JP6484216B2 JP6484216B2 (ja) | 2019-03-13 |
Family
ID=50549463
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502232A Active JP6484216B2 (ja) | 2013-03-15 | 2014-03-13 | Ａｄａｍｔｓ１３の皮下投与 |
| JP2019025097A Active JP6998333B2 (ja) | 2013-03-15 | 2019-02-15 | Ａｄａｍｔｓ１３の皮下投与 |
| JP2021205839A Active JP7238088B2 (ja) | 2013-03-15 | 2021-12-20 | Ａｄａｍｔｓ１３の皮下投与 |
| JP2023030589A Pending JP2023071821A (ja) | 2013-03-15 | 2023-03-01 | Ａｄａｍｔｓ１３の皮下投与 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019025097A Active JP6998333B2 (ja) | 2013-03-15 | 2019-02-15 | Ａｄａｍｔｓ１３の皮下投与 |
| JP2021205839A Active JP7238088B2 (ja) | 2013-03-15 | 2021-12-20 | Ａｄａｍｔｓ１３の皮下投与 |
| JP2023030589A Pending JP2023071821A (ja) | 2013-03-15 | 2023-03-01 | Ａｄａｍｔｓ１３の皮下投与 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9611467B2 (enExample) |
| EP (2) | EP2968483B1 (enExample) |
| JP (4) | JP6484216B2 (enExample) |
| KR (5) | KR102513872B1 (enExample) |
| CN (2) | CN114259558A (enExample) |
| AU (5) | AU2013203062C1 (enExample) |
| BR (1) | BR112015023542A8 (enExample) |
| CA (1) | CA2905058A1 (enExample) |
| DK (1) | DK2968483T3 (enExample) |
| EA (2) | EA201992832A1 (enExample) |
| ES (1) | ES2906550T3 (enExample) |
| IL (3) | IL241305B (enExample) |
| MX (2) | MX380485B (enExample) |
| PL (1) | PL2968483T3 (enExample) |
| PT (1) | PT2968483T (enExample) |
| SG (3) | SG10202001227QA (enExample) |
| TW (4) | TWI690326B (enExample) |
| WO (1) | WO2014151968A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203062C1 (en) * | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
| GB201510870D0 (en) * | 2015-05-26 | 2015-08-05 | Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh | Treatment of infarction |
| NZ750146A (en) | 2016-08-04 | 2025-10-31 | Takeda Pharmaceuticals Co | Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome |
| WO2020214033A1 (en) * | 2019-04-17 | 2020-10-22 | Erasmus University Medical Center Rotterdam | Papain-like cysteine peptidase medicaments and uses thereof |
| WO2021067668A1 (en) | 2019-10-04 | 2021-04-08 | The Children's Medical Center Corporation | Adamts13 treatment to enhance graft survival |
| AU2021248679A1 (en) * | 2020-04-02 | 2022-10-27 | Takeda Pharmaceutical Company Limited | ADAMTS13 variant, compositions, and uses thereof |
| WO2021234458A1 (en) | 2020-05-22 | 2021-11-25 | Takeda Pharmaceutical Company Limited | Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease |
| CA3179894A1 (en) * | 2020-05-25 | 2021-12-02 | Sanquin IP B.V. | Adamts13 protein variants and uses thereof |
| US20230405096A1 (en) * | 2020-11-18 | 2023-12-21 | Green Cross Corporation | Adamts13 variant having increased escaping rate or activity against autoantibody |
| GB202102208D0 (en) * | 2021-02-17 | 2021-03-31 | Univ Manchester | Adamts13 variant |
| WO2024151093A1 (ko) * | 2023-01-11 | 2024-07-18 | 주식회사 녹십자 | 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| US6926894B2 (en) | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
| US7037658B2 (en) * | 2001-08-16 | 2006-05-02 | Regents Of University Of Michigan | Methods and compositions for detecting variant ADAMTS13 genes |
| US7763430B2 (en) | 2003-04-22 | 2010-07-27 | Baxter International Inc. | Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies |
| AU2006257073B2 (en) * | 2005-06-17 | 2011-08-04 | Children's Medical Center Corporation | ADAMTS13-comprising compositions having thrombolytic activity |
| JP2009539757A (ja) * | 2006-06-16 | 2009-11-19 | バクスター・インターナショナル・インコーポレイテッド | 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物 |
| US20090317375A1 (en) * | 2008-05-12 | 2009-12-24 | Immune Disease Institute, Inc. | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction |
| CA2770609A1 (en) * | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| JP5819303B2 (ja) * | 2009-09-21 | 2015-11-24 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 安定化された液体および凍結乾燥ａｄａｍｔｓ１３製剤 |
| ES3037386T3 (en) * | 2010-07-08 | 2025-10-01 | Takeda Pharmaceuticals Co | Method of producing recombinant high molecular weight vwf in cell culture |
| AU2013203062C1 (en) | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
-
2013
- 2013-04-09 AU AU2013203062A patent/AU2013203062C1/en active Active
-
2014
- 2014-03-13 EA EA201992832A patent/EA201992832A1/ru unknown
- 2014-03-13 PL PL14719469T patent/PL2968483T3/pl unknown
- 2014-03-13 US US14/210,167 patent/US9611467B2/en active Active
- 2014-03-13 CN CN202111631652.1A patent/CN114259558A/zh active Pending
- 2014-03-13 WO PCT/US2014/026747 patent/WO2014151968A1/en not_active Ceased
- 2014-03-13 EP EP14719469.0A patent/EP2968483B1/en active Active
- 2014-03-13 SG SG10202001227QA patent/SG10202001227QA/en unknown
- 2014-03-13 KR KR1020227005350A patent/KR102513872B1/ko active Active
- 2014-03-13 DK DK14719469.0T patent/DK2968483T3/da active
- 2014-03-13 KR KR1020217004442A patent/KR102365936B1/ko active Active
- 2014-03-13 ES ES14719469T patent/ES2906550T3/es active Active
- 2014-03-13 PT PT147194690T patent/PT2968483T/pt unknown
- 2014-03-13 CN CN201480027202.3A patent/CN105407912A/zh active Pending
- 2014-03-13 CA CA2905058A patent/CA2905058A1/en active Pending
- 2014-03-13 SG SG10201707074TA patent/SG10201707074TA/en unknown
- 2014-03-13 SG SG11201507271QA patent/SG11201507271QA/en unknown
- 2014-03-13 KR KR1020197005635A patent/KR102102087B1/ko active Active
- 2014-03-13 EP EP21203692.5A patent/EP3960196A1/en active Pending
- 2014-03-13 MX MX2015012783A patent/MX380485B/es unknown
- 2014-03-13 BR BR112015023542A patent/BR112015023542A8/pt not_active Application Discontinuation
- 2014-03-13 JP JP2016502232A patent/JP6484216B2/ja active Active
- 2014-03-13 KR KR1020157028432A patent/KR20160016756A/ko not_active Ceased
- 2014-03-13 KR KR1020207010406A patent/KR102218489B1/ko active Active
- 2014-03-13 EA EA201591758A patent/EA034546B1/ru not_active IP Right Cessation
- 2014-03-14 TW TW103109832A patent/TWI690326B/zh active
- 2014-03-14 TW TW108133433A patent/TWI740207B/zh active
- 2014-03-14 TW TW110108163A patent/TWI786563B/zh active
- 2014-03-14 TW TW111144983A patent/TW202313664A/zh unknown
-
2015
- 2015-09-08 IL IL241305A patent/IL241305B/en active IP Right Grant
- 2015-09-14 MX MX2021002513A patent/MX2021002513A/es unknown
-
2016
- 2016-09-22 AU AU2016231547A patent/AU2016231547B2/en active Active
-
2017
- 2017-02-22 US US15/439,154 patent/US10413600B2/en active Active
-
2018
- 2018-05-24 AU AU2018203665A patent/AU2018203665B2/en active Active
-
2019
- 2019-02-15 JP JP2019025097A patent/JP6998333B2/ja active Active
- 2019-09-11 US US16/567,048 patent/US11185575B2/en active Active
-
2020
- 2020-03-17 IL IL273365A patent/IL273365B/en unknown
- 2020-04-23 AU AU2020202738A patent/AU2020202738B2/en active Active
-
2021
- 2021-11-12 US US17/525,759 patent/US11779635B2/en active Active
- 2021-12-20 JP JP2021205839A patent/JP7238088B2/ja active Active
-
2022
- 2022-02-09 IL IL290486A patent/IL290486B2/en unknown
- 2022-08-05 AU AU2022211908A patent/AU2022211908B2/en active Active
-
2023
- 2023-03-01 JP JP2023030589A patent/JP2023071821A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016517421A5 (enExample) | ||
| Owusu-Ansah et al. | Inflammatory targets of therapy in sickle cell disease | |
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| JP2015517488A5 (enExample) | ||
| JP2015518818A5 (enExample) | ||
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| JP2016516016A5 (enExample) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| MD20150120A2 (ro) | Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei | |
| JP2014526541A5 (enExample) | ||
| JP2017501154A5 (enExample) | ||
| JP2017519799A5 (enExample) | ||
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2013040195A5 (enExample) | ||
| JP2016512247A5 (enExample) | ||
| JP2014530246A5 (enExample) | ||
| RU2017129068A (ru) | Способ лечения или профилактики атеротромботических явлений у пациентов с инфарктом миокарда в анамнезе | |
| JP2020510043A5 (enExample) | ||
| JP2016520114A5 (enExample) | ||
| JP2016515137A5 (enExample) | ||
| RU2016103098A (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii | |
| WO2014165829A3 (en) | Nanoparticle formulations | |
| WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2019535830A5 (enExample) | ||
| CN107921019B (zh) | 2-(5s-甲基-2-氧代-4r-苯基-吡咯烷-1-基)-乙酰胺在治疗病情发作中的应用 |